This person is not registered. Is this you?


Profile Details
Yihong Qiu
Affiliations:

Abbott Laboratories

 
,
Phone:
Fax:
My Blogs:
My Twitter Hashtags:
@YLindaQiu
 
Age:
Bio:
 
Specialty:
Cancer Biology, Cancer Immunotherapy
 
Presented at Events Covering:
 
Areas of Interest:
 
Hobbies:
 
General Comments:
BSN Rank: 5021 / 3065 (What's this?)
Accomplish Score: 36
Popularity Score: Unavailable
# in My Circle: 0
# in My Org(s): 82
We'll Post Your CV for Free!
 
 
Speaking/Presenting-Abstract/Poster at Mtg: 0 (0 / 0)
 
Honors and Awards: 0 (0 / 0)
 
Clinical Trial Activity: 0 (0 / 0)
 
Grant Support: 0 (0 / 0)
 
Patents Pending: 0 (0 / 0)
 
Journal - Editor/Reviewer: 0 (0 / 0)
 
Peer Reviewed Papers, Books, Chapters: 6 (36 / 0)
  • PURPOSE: Metastasis and local recurrence are the primary causes of treatment failure and patient death in breast cancer. ()
  • OBJECTIVE: Erlotinib has a synergistic effect with pemetrexed for treating non-squamous non-small-cell lung cancer. ()
  • Efficacy of EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, to treat human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR is not persistent due to drug resistance. ()
 
Pre/Non Reviewed Papers, Proceedings: 0 (0 / 0)
 
Membership in Professional Societies: 0 (0 / 0)
 
White Papers: 0 (0 / 0)
 
Registered on BiotechScienceNews: 0

3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.